Suppr超能文献

全系统阿育吠陀疗法治疗肠易激综合征的疗效——一项随机对照临床试验

Efficacy of whole system ayurveda protocol in irritable bowel syndrome - A Randomized controlled clinical trial.

作者信息

Naik Teja D, Tubaki Basavaraj R, Patankar Devayani S

机构信息

Department of Kayachikitsa, Shri BMK Ayurveda Mahavidyalaya, A Constituent Unit of KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590003, India.

Department of Kayachikitsa, Shri BMK Ayurveda Mahavidyalaya, A Constituent Unit of KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590003, India.

出版信息

J Ayurveda Integr Med. 2023 Jan-Feb;14(1):100592. doi: 10.1016/j.jaim.2022.100592. Epub 2022 Nov 9.

Abstract

BACKGROUND

Irritable bowel syndrome (IBS) is one of the clinically challenging disorders. It has a significant effect on health, cost and quality of life. Ayurveda management through whole system approach in IBS is explored.

OBJECTIVE

To evaluate the efficacy of whole system Ayurveda approach in IBS.

METHODS

The present trial is a randomized controlled parallel group study. 48 patients diagnosed as IBS (Rome IV Criteria) between the age group of 20-60 yrs were recruited in the study. Patients were randomly divided into 2 groups. KC group intervened with Kalingadi Churna 3 gm twice a day, before food with buttermilk. WS group intervened with whole system ayurveda protocol (WSAP). Duration of intervention was 60 days with follow up on every 15th day. Assessments were through various clinical measures like IBS Symptom Severity Score (IBS-SSS), IBS Adequate Relief (IBS-AR), Gastrointestinal symptom rating scale (GSRS), IBS-VAS, Complete Spontaneous Bowel Movements (CSBMs), Bristol Stool Form (BSF), Hamilton Anxiety Rating Scale (HARS), Hamilton Depression Rating Scale (HDRS), IBS quality of life (IBS-QoL) at every follow up. Hemoglobin, Erythrocyte sedimentation rate and stool examination was conducted at pre and post study.

RESULTS

Study showed that WS group had significant improvement compared to KC group in IBS-SSS, IBS-AR, IBS-VAS, CSBM, BSF-Diarrhea and BSF-Constipation. Both groups were comparable in GSRS, HARS, HDRS and IBS-QOL. Blood and stool parameters assessments showed comparable improvements in both the groups. Within group significant improvements in all the clinical assessment scales were observed in both the groups.

CONCLUSION

WSAP was effective in management of IBS (IBS constipation and IBS diarrhea). Improvements were observed in abdominal pain, stool frequency, consistency and adequate relief.

摘要

背景

肠易激综合征(IBS)是临床上具有挑战性的疾病之一。它对健康、成本和生活质量有重大影响。本文探讨了阿育吠陀整体系统疗法对肠易激综合征的治疗效果。

目的

评估阿育吠陀整体系统疗法对肠易激综合征的疗效。

方法

本试验为随机对照平行组研究。招募了48名年龄在20至60岁之间、被诊断为肠易激综合征(符合罗马IV标准)的患者。患者被随机分为两组。KC组每天两次,每次3克卡林加迪药粉,饭前与酪乳一起服用。WS组采用阿育吠陀整体系统疗法方案(WSAP)进行干预。干预持续时间为60天,每15天进行一次随访。通过各种临床指标进行评估,如肠易激综合征症状严重程度评分(IBS-SSS)、肠易激综合征充分缓解率(IBS-AR)、胃肠道症状评分量表(GSRS)、肠易激综合征视觉模拟量表(IBS-VAS)、完全自主排便次数(CSBMs)、布里斯托大便分型(BSF)、汉密尔顿焦虑评定量表(HARS)、汉密尔顿抑郁评定量表(HDRS)、每次随访时的肠易激综合征生活质量(IBS-QoL)。在研究前后进行血红蛋白、红细胞沉降率和粪便检查。

结果

研究表明,与KC组相比,WS组在IBS-SSS、IBS-AR、IBS-VAS、CSBM、BSF-腹泻型和BSF-便秘型方面有显著改善。两组在GSRS、HARS、HDRS和IBS-QOL方面具有可比性。血液和粪便参数评估显示两组有类似的改善。两组在所有临床评估量表上均观察到组内显著改善。

结论

WSAP对肠易激综合征(便秘型和腹泻型)的治疗有效。在腹痛、大便频率、性状及充分缓解方面均有改善。

相似文献

1
Efficacy of whole system ayurveda protocol in irritable bowel syndrome - A Randomized controlled clinical trial.
J Ayurveda Integr Med. 2023 Jan-Feb;14(1):100592. doi: 10.1016/j.jaim.2022.100592. Epub 2022 Nov 9.
2
Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial.
J Ayurveda Integr Med. 2024 Mar-Apr;15(2):100896. doi: 10.1016/j.jaim.2024.100896. Epub 2024 Apr 11.
4
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.
6
Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
J Clin Gastroenterol. 2011 Oct;45(9):790-3. doi: 10.1097/MCG.0b013e3182053cea.
7
Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1946-54.e1. doi: 10.1016/j.cgh.2015.06.022. Epub 2015 Jun 29.
8
Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study.
World J Gastrointest Pharmacol Ther. 2023 Dec 12;14(5):39-49. doi: 10.4292/wjgpt.v14.i5.39.

引用本文的文献

1
Add on effect of Whole System Ayurveda protocol in suboptimal controlled Primary Hypothyroidism - A randomized controlled trial.
J Ayurveda Integr Med. 2025 Jan-Feb;16(1):101052. doi: 10.1016/j.jaim.2024.101052. Epub 2025 Jan 10.

本文引用的文献

1
Ayurveda management of Major Depressive Disorder: A case study.
J Ayurveda Integr Med. 2021 Apr-Jun;12(2):378-383. doi: 10.1016/j.jaim.2021.03.012. Epub 2021 May 20.
2
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20.
3
Whole Systems Research Methods in Health Care: A Scoping Review.
J Altern Complement Med. 2019 Mar;25(S1):S21-S51. doi: 10.1089/acm.2018.0499.
5
What Is New in Rome IV.
J Neurogastroenterol Motil. 2017 Apr 30;23(2):151-163. doi: 10.5056/jnm16214.
6
Irritable bowel syndrome.
Nat Rev Dis Primers. 2016 Mar 24;2:16014. doi: 10.1038/nrdp.2016.14.
8
Towards a systems view of IBS.
Nat Rev Gastroenterol Hepatol. 2015 Oct;12(10):592-605. doi: 10.1038/nrgastro.2015.121. Epub 2015 Aug 25.
9
Pharmacology of Ativisha, Musta and their substitutes.
J Ayurveda Integr Med. 2015 Apr-Jun;6(2):121-33. doi: 10.4103/0975-9476.146551.
10
Self-regulation evaluation of therapeutic yoga and walking for patients with irritable bowel syndrome: a pilot study.
Psychol Health Med. 2016;21(2):176-88. doi: 10.1080/13548506.2015.1051557. Epub 2015 Jun 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验